SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (50)5/18/1999 8:52:00 PM
From: Miljenko Zuanic  Read Replies (1) of 226
 
Curtis:

First, I will refer this questions to SI experts on mAb and vaccines, RH and PB.

Last year I saw oncologist excitement about immuno/vaccines approach to cancer therapy. It appears that this year they cooled down bit.

Theratope Bridging Study data (new drug formulation) seams OK, vaccines safety and benefit correlate good.

However, there is one trick, related to ongoing discussion over high-dose chemotherapy and autologous stem cell rescue. As you know this approach (very expensive) didn't show any additional benefit over standard chemotherapy. So, it may be drooped as new standard therapy for late stage and metastatic (stage III/IV) breast cancer.

Do you know what is Theratope protocol in PIII trial?

If some as in old PII and Bridge study, Biomira will probably (IMO) need to modify protocol or run new PIII trials (or PII/III).

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News